Suppr超能文献

特发性嗜睡症严重程度量表,用于更好地量化特发性嗜睡症的症状严重程度及其后果。

Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia.

机构信息

CHU Montpellier, Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France.

Institute Neurosciences of Montellier, Université de Montpellier, INSERM, Montpellier, France.

出版信息

J Clin Sleep Med. 2022 Feb 1;18(2):617-629. doi: 10.5664/jcsm.9682.

Abstract

STUDY OBJECTIVES

To assess the responsiveness of the Idiopathic Hypersomnia Severity Scale (IHSS) to medications and estimate the minimum clinically important difference, to report clinically relevant score ranges, and to confirm its psychometric properties and whether items need to be weighted in drug-free and treated patients with idiopathic hypersomnia (IH).

METHODS

Two-hundred twenty-six (166 drug-free and 60 treated) patients with IH (cross-sectional sample) completed the 14-item IHSS to quantify the severity of the 3 major IH symptoms (excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia) and consequences; 77 untreated patients were evaluated again after treatment (longitudinal sample). Patients filled in the Epworth Sleepiness Scale, Beck Depression Inventory II, and European Quality of Life questionnaires.

RESULTS

The IHSS confirmed adequate psychometric properties with a factor analysis indicating a 3-component solution. IHSS total score was lower in treated than untreated patients, with a mean difference of 4-5 points in the cross-sectional and longitudinal samples. Distribution-based methods were used to estimate that 4 points represented the minimum clinically important difference. Four severity levels were defined with between-group differences related to treatment. The probability of having severe sleepiness, depressive symptoms, and low quality of life increased with the severity level. Our results showed that IHSS item-weighting was not necessary.

CONCLUSIONS

The IHSS is a valid and reliable tool to quantify IH symptoms, with 4 severity score levels of clinical importance. The IHSS has adequate psychometric properties and can detect symptom changes after treatment. These findings should stimulate its use in clinical settings and in research studies.

CITATION

Rassu AL, Evangelista E, Barateau L, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. . 2022;18(2):617-629.

摘要

研究目的

评估特发性嗜睡症严重程度量表(IHSS)对药物的反应性,并估计最小临床重要差异,报告具有临床意义的评分范围,并确认其心理测量特性以及在未经药物治疗和接受治疗的特发性嗜睡症(IH)患者中是否需要对项目进行加权。

方法

226 名(166 名未接受药物治疗和 60 名接受治疗)特发性嗜睡症患者(横断面样本)完成了 14 项 IHSS,以量化 3 种主要 IH 症状(白天过度嗜睡、延长夜间睡眠时间和睡眠惯性)和后果的严重程度;77 名未经治疗的患者在治疗后再次进行评估(纵向样本)。患者填写了 Epworth 嗜睡量表、贝克抑郁量表 II 和欧洲生活质量问卷。

结果

IHSS 通过因素分析确认了足够的心理测量特性,表明存在 3 个组成部分的解决方案。与未经治疗的患者相比,接受治疗的患者 IHSS 总分较低,横断面和纵向样本中的平均差异为 4-5 分。基于分布的方法用于估计 4 分代表最小临床重要差异。使用 4 个严重程度水平定义,组间差异与治疗相关。严重嗜睡、抑郁症状和生活质量低的可能性随着严重程度的增加而增加。我们的结果表明,IHSS 项目加权不是必需的。

结论

IHSS 是一种有效且可靠的工具,可用于量化 IH 症状,具有 4 个具有临床重要性的严重程度评分水平。IHSS 具有足够的心理测量特性,可以检测治疗后的症状变化。这些发现应该刺激其在临床环境和研究中的使用。

相似文献

3
特发性嗜睡症症状的测量:特发性嗜睡症严重程度量表。
Neurology. 2019 Apr 9;92(15):e1754-e1762. doi: 10.1212/WNL.0000000000007264. Epub 2019 Mar 13.
6
新冠疫情封锁期间发作性睡病、特发性嗜睡症和不安腿综合征患者睡眠模式的变化。
Neurology. 2022 Oct 4;99(14):e1475-e1485. doi: 10.1212/WNL.0000000000200907. Epub 2022 Aug 2.
10
特发性嗜睡症中自主神经症状的频率和严重程度。
J Clin Sleep Med. 2020 May 15;16(5):749-756. doi: 10.5664/jcsm.8344. Epub 2020 Feb 10.

引用本文的文献

2
发作性睡病中枢性障碍的现状与未来。
J Sleep Res. 2025 Oct;34(5):e70118. doi: 10.1111/jsr.70118. Epub 2025 Jun 18.
5
患有中枢性过度嗜睡症个体的功能连接性及时空动态变化。
Front Neurosci. 2025 Mar 25;19:1538479. doi: 10.3389/fnins.2025.1538479. eCollection 2025.
7
特发性嗜睡症的诊断挑战与负担:一项系统文献综述
Sleep Adv. 2024 Aug 16;5(1):zpae059. doi: 10.1093/sleepadvances/zpae059. eCollection 2024.
8
睡眠惯性问卷在中枢性嗜睡障碍中的验证和性能。
Sleep Med. 2024 Sep;121:352-358. doi: 10.1016/j.sleep.2024.07.024. Epub 2024 Jul 23.

本文引用的文献

3
特发性嗜睡症患者的疾病症状和治疗反应:嗜睡症基金会登记处的初步数据。
Sleep Med. 2020 Nov;75:343-349. doi: 10.1016/j.sleep.2020.08.034. Epub 2020 Sep 2.
4
中枢性嗜睡障碍的诊断:欧洲专家的再评估。
Sleep Med Rev. 2020 Aug;52:101306. doi: 10.1016/j.smrv.2020.101306. Epub 2020 Mar 23.
5
分还是合?中枢性嗜睡症的分类。
Sleep. 2020 Aug 12;43(8). doi: 10.1093/sleep/zsaa044.
6
药物治疗对发作性睡病和特发性嗜睡症队列患者报告结局的影响。
J Clin Sleep Med. 2019 Dec 15;15(12):1799-1806. doi: 10.5664/jcsm.8088. Epub 2019 Oct 30.
7
特发性嗜睡症症状的测量:特发性嗜睡症严重程度量表。
Neurology. 2019 Apr 9;92(15):e1754-e1762. doi: 10.1212/WNL.0000000000007264. Epub 2019 Mar 13.
8
特发性嗜睡症的替代诊断标准:32 小时方案。
Ann Neurol. 2018 Feb;83(2):235-247. doi: 10.1002/ana.25141. Epub 2018 Feb 9.
9
特发性嗜睡症的治疗进展
Expert Opin Investig Drugs. 2018 Feb;27(2):187-192. doi: 10.1080/13543784.2018.1417385. Epub 2018 Jan 3.
10
多发性睡眠潜伏期试验在中枢性嗜睡障碍中的重测信度。
Sleep. 2017 Dec 1;40(12). doi: 10.1093/sleep/zsx164.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验